- •It is very difficult to achieve an adequate lipid control, even under a close follow-up and a structured CRP.
- •Women represent a minority of patients performing CRP.
- •Unlike other reports, in our cohort, women received more potent anti-dyslipidemic therapy.
- •Women showed a poor control of LDL-concentration after three months of ACS even under more potent anti-dyslipidemic therapy.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Lancet. 1994; 344: 1383-1389
- Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N. Engl. J. Med. 2004; 350: 1495-1504
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials.Lancet. 2010; 376: 1670-1681
- Ezetimibe added to statin therapy after acute coronary syndromes.N. Engl. J. Med. 2015; 372: 2387-2397
- Evolocumab and clinical outcomes in patients with cardiovascular disease.N. Engl. J. Med. 2017; 376: 1713-1722
- Alirocumab and cardiovascular outcomes after acute coronary syndrome.N. Engl. J. Med. 2018; 379: 2097-2107
- 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.Eur. Heart J. 2018; 39: 119-177
- Heart disease and stroke statistics—2022 update: a report from the American Heart Association [published online ahead of print Wednesday, January 26, 2022].Circulation. 2022; https://doi.org/10.1161/CIR.0000000000001052
- 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes.Eur. Heart J. 2020; 41: 407-477
- ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Vol. 42.Eur. Heart J. 2020; 2021: 1289-1367
- Women Are Less Likely to Get Secondary Prevention Medications and Cardiac Rehabilitation [Internet]. Clinical Topics. American College of Cardiology.(Available from:)https://www.acc.org/latest-in-cardiology/articles/2017/10/30/15/02/women-are-less-likely-to-get-secondary-prevention-medications-and-crDate: 2017
- Secondary prevention after acute coronary syndrome: are dyslipidaemia guideline targets achieved? Eur.J. Prev. Cardiol. 2022; 29: E122-E124
- Exercise-based cardiac rehabilitation for coronary heart disease (review).Cochrane Database Syst. Rev. 2016; 1: 1-211
- Lessons learned from community-and home-based physical activity programs: a narrative review of factors influencing women’s participation in cardiac rehabilitation.Eur. J. Prev. Cardiol. 2021; 28: 761-778
- Cardiac rehabilitation in women: state of the art and strategies to overcome the current barriers.J. Cardiovasc. Med. 2018; 19: 689-697
- Women and cardiac rehabilitation: moving beyond barriers to solutions?.Eur. J. Prev. Cardiol. 2021; 28: 758-760
- Women and ischemic heart disease. Evolving knowledge.J. Am. Coll. Cardiol. 2009; 54: 1561-1575
- Statin therapy in the prevention of recurrent cardiovascular events a sex-based meta-analysis.Arch. Intern. Med. 2012; 172: 909-919
- Meta-analysis of statin effects in women versus men.J. Am. Coll. Cardiol. 2012; 59: 572-582
- Benefit of intensive statin therapy in women results from PROVE IT-TIMI 22.Circ. Cardiovasc. Qual. Outcomes. 2011; 4: 328-336